VJOncology

EV-103 Cohort K: long-term outcomes of EV ± pembrolizumab in la/mUC - VJOncology Terence Friedlander, MD, University of California, San Francisco, CA, discusses updated results from Cohort K of the Phase Ib/II EV-103...

Terence Friedlander, MD, shares 3.5-year #EV103 Cohort K data at #ESMO25 — enfortumab vedotin + pembrolizumab continues to show durable responses & survival benefits in 1L la/mUC.

🎥 Watch: buff.ly/kWn5KkI

#UroOnc #UroSoMe #Blcsm #ImmunoOnc #CTSM #TrialUpdate

EMPRESS: giredestrant vs tamoxifen in ER+/HER2- early breast cancer - VJOncology Antonio Llombart Cussac, MD, PhD, Arnau de Vilanova Hospital of Valencia, Valencia, Spain, discusses results from the Phase II EMPRESS...

At #ESMO25, Dr Llombart Cussac presents #EMPRESS trial results: giredestrant led to greater Ki67 reduction and stronger ER/PR decreases vs tamoxifen in premenopausal ER+/HER2- early #BreastCancer.

🎥 Watch: buff.ly/vLWxnoe

#BCSM #CTSM #TrialUpdate #Oncology

Metastatic breast cancer updates at ESMO 2025 - VJOncology Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, University of Hong Kong, Hong Kong, China, provides an overview of the metastatic breast...

🎥Janice Wing-Hang Tsang, MBBS, MRCP, FRCP, @HKUniversity, shares highlights from the #MetastaticBreastCancer track at #ESMO25 - including updates from VIKTORIA-1, novel ADCs in #TNBC, and PRO/QoL insights.

Watch here ➡️ buff.ly/E4FLjXD

#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #ESMO25

RENALUT: 177Lu-PSMA-617 in metastatic pre-treated ccRCC - VJOncology Emmanuel Seront, MD, PhD, Cliniques Universitaires Saint Luc, Brussels, Belgium, discusses the Phase II RENALUT (NCT06783348) of 177Lu-PSMA-617 in patients...

Emmanuel Seront, MD, PhD, discusses the Phase II RENALUT trial of 177Lu-PSMA-617 in metastatic ccRCC post-TKI/IO therapy, exploring PSMA-targeted radioligand therapy as a new option for resistant disease

🎥 buff.ly/dLhijGf

#KidneyCancer #KCSM #CTSM #TrialUpdate #RadioligandTherapy #RadOnc #ESMO25

DESTINY-Breast05: T-DXd vs T-DM1 in high-risk HER2+ early breast cancer - VJOncology Charles Geyer, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, discusses results from the Phase III DESTINY-Breast05 trial (NCT04622319), comparing...

Charles Geyer, MD, reports #DESTINYBreast05 results in HER2+ early BC.

💊 T-DXd > T-DM1 for iDFS & DFS
🧠 Reduced brain mets risk
⚖️ Manageable safety → potential new SoC

🎥 buff.ly/r3AwOkw

#BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc #Immunotherapy #HER2 #ESMO25 @myesmo.bsky.social

PATHFINDER II: assessing the efficacy and safety of a MCAD test - VJOncology Nima Nabavizadeh, MD, Oregon Health & Science University, Portland, OR, discusses the PATHFINDER II study (NCT05155605), evaluating a multi-cancer early...

Nima Nabavizadeh, MD, presents #PATHFINDERII data on multi-cancer early detection.

🧬 cfDNA test detects cancer signal & origin
📈 High specificity & PPV
⚕️ Boosted early-stage cancer detection

🎥 buff.ly/LDR0AgW

#CancerScreening #Oncology #ESMO25

EMBARK: final OS results of enzalutamide in hrBCR prostate cancer - VJOncology Neal Shore, MD, FACS, Carolina Urologic Research Center, Myrtle Beach, SC, discusses final overall survival results from the Phase III...

Neal Shore, MD, FACS shares final OS data from EMBARK in high-risk BCR prostate cancer.

💊 Enzalutamide + leuprolide ↓ risk of death vs leuprolide alone
📈 Improved progression & skeletal outcomes
✅ Confirms enzalutamide-based therapy as SoC
🎥 buff.ly/LBEmrOa

#ProstateCancer #ESMO25 #UroOnc #UroSoMe

FORAGER-1: dose optimization of LY3866288 in FGFR3-altered tumors - VJOncology Alexandra Drakaki, MD, PhD, University of California, Los Angeles, CA, discusses the Phase I FORAGER-1 study (NCT05614739) of LY3866288, a...

Alexandra Drakaki, MD, PhD, discusses FORAGER-1 testing LY3866288 in FGFR3-altered tumors

🧬 200 mg BID = well tolerated
💥 Encouraging antitumor activity in mUC
🧪 Activity seen post-FGFR inhibitor exposure

🎥 buff.ly/ozWqgdG

#BladderCancer #Blcsm #UroOnc #UroSoMe #CTSM #TrialUpdate #ESMO25

EMERALD: eribulin plus dual HER2 blockade in first-line HER2+ breast cancer - VJOncology Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, comments on discusses final survival results from the EMERALD study (NCT03264547)...

Shigehira Saji, MD, PhD, shares final OS data from EMERALD in 1L HER2+ #BreastCancer.

💊 Eribulin or taxane + trastuzumab + pertuzumab
📈 Median OS >6 years, similar across arms
🧬 PIK3CA = poor prognosis, no impact on treatment effect
🎥 buff.ly/R9sZAVk

#BCSM #TrialUpdate #CTSM #ImmunoOnc #ESMO25

ADRISK: pembrolizumab plus adjuvant chemoradiation in HNSCC - VJOncology Andreas Dietz, MD, PhD, University Hospital of Leipzig, Leipzig, Germany, discusses the Phase IIb ADRISK trial (NCT03480672), which evaluated pembrolizumab...

Andreas Dietz, MD, PhD, discusses the ADRISK Phase IIb trial in adjuvant HNSCC.

💉 Pembrolizumab + chemoradiation
➡️ No sig. EFS/OS gain, but favorable trends
⚖️ Safety consistent; supports further study
🎥 buff.ly/NlJqVv0

#HNSCC #Immunotherapy #Oncology #ESMO25

DISCUS: comparing 3 vs 6 chemotherapy cycles before avelumab in aUC - VJOncology Enrique Grande, MD, MD Anderson Cancer Center Madrid, Madrid, Spain, discusses the Phase II DISCUS trial (NCT06892860), which evaluated whether...

At #ESMO25, Enrique Grande, MD, presents results from the Phase II DISCUS trial in aUC.

💊 3 vs 6 chemo cycles before avelumab maintenance
📈 Similar OS & PFS
💪 Better QoL & fewer toxicities with 3 cycles

🎥 buff.ly/UjqkfNT

@myesmo.bsky.social #BladderCancer #ImmunoOnc #GUcancer #Oncology

COSMIC-313: transcriptomic predictors of metastatic sites in RCC - VJOncology Clara Steiner, MD, Dana-Farber Cancer Institute, Boston, MA & University Hospital Leipzig, Leipzig, Germany, discusses a post-hoc transcriptomic analysis from...

Clara Steiner, MD, presents new transcriptomic findings from COSMIC-313 in #RCC at #ESMO25

🧬 RNA sequencing of baseline tumors
🔍 Distinct gene signatures by metastasis site
🌡️ Pathways: metabolism, hypoxia, EMT

🎥 Watch: buff.ly/dIMvnoC

@myesmo.bsky.social #KCSM #CTSM #TrialUpdate #UroOnc #UroSoMe

IMvigor011: ctDNA-guided adjuvant atezolizumab in MIBC - VJOncology Alexander Wyatt, DPhil, University of British Columbia, Vancouver, Canada, discusses the Phase III IMvigor011 trial (NCT04660344) of circulating tumor (ctDNA)-guided...

Alexander Wyatt, DPhil, shares IMvigor011 results of ctDNA-guided adjuvant atezolizumab in high-risk #BladderCancer:

🧬 Atezolizumab improved DFS & OS in ctDNA+ pts
🚫 ctDNA– pts had low recurrence risk
✅ Safety consistent with known profile

🎥 Watch: buff.ly/g35zqx2

@myesmo.bsky.social #ESMO25

MonarchE: Ki-67 dynamics and prognostic value in HR+/HER2- breast cancer - VJOncology Shigehira Saji, MD, PhD, Fukushima Medical University, Fukushima, Japan, discusses the MonarchE trial (NCT03155997) evaluating the prognostic and predictive value...

At #ESMO25, Shigehira Saji shares new MonarchE data on Ki-67 as a biomarker in HR+/HER2– high-risk #BreastCancer:

📊 High Ki-67 = ↑ recurrence risk
💊 Abemaciclib + ET effective across all Ki-67 subgroups
✅ Broad benefit, regardless of Ki-67 change

🎥 Watch: buff.ly/F1mziDY

#BCSM #CTSM #TrialUpdate

PSMAddition: 177Lu-PSMA-617 plus ADT and ARPI in PSMA-positive mHSPC - VJOncology Scott Tagawa, MD, MS, FACP, Weill Cornell Medical Center, New York, NY, discusses the Phase III PSMAddition trial (NCT04720157), which...

At #ESMO25, Scott Tagawa, MD, MS, FACP, discusses the Phase III PSMAddition trial in PSMA-positive mHSPC:

💥 Adding ¹⁷⁷Lu-PSMA-617 to ADT + ARPI improved rPFS
📈 OS trend & manageable safety
✅ No major QoL impact

🎥 Watch: buff.ly/vSBfVPS

@myesmo.bsky.social #PCSM #UroOnc #UroSoMe #RadOnc #CTSM

CheckMate 274: 5-year results of adjuvant nivolumab in MIUC - VJOncology Clara Steiner, MD, Dana-Farber Cancer Institute, Boston, MA & University Hospital Leipzig, Leipzig, Germany, gives an overview of updated 5-year...

At #ESMO25, Clara Steiner, MD, presents 5-year results of CheckMate 274 in MIUC

💊 Adjuvant nivolumab vs placebo after surgery
📈 Sustained DFS, OS & disease-specific survival benefit
🧫 ctDNA-positive pts saw enhanced benefit
✅ No new safety concerns

🎥 Watch: buff.ly/ou4EvLv

#UroOnc #UroSoMe #Blcsm

Ask the Expert: Stephanie Graff answers your breast cancer questions at ESMO 2025 - VJOncology Stephanie Graff, MD, Brown University Health Cancer Institute, Providence, RI, joins us for an “Ask the Expert” session at ESMO...

At #ESMO25, Stephanie Graff, MD, addresses key questions in #BreastCancer care.

💊 Updates on CDK4/6 inhibitors
💪 Managing endocrine therapy toxicities
🌍 Global survivorship & trial access insights

🎥 Watch the full session: buff.ly/LdOXB18

#BCSM #Oncology

RENALUT: 177Lu-PSMA-617 in metastatic pre-treated ccRCC - VJOncology Emmanuel Seront, MD, PhD, Cliniques Universitaires Saint Luc, Brussels, Belgium, discusses the Phase II RENALUT (NCT06783348) of 177Lu-PSMA-617 in patients...

At #ESMO25, Emmanuel Seront discusses the RENALUT trial of ¹⁷⁷Lu-PSMA-617 in metastatic ccRCC

💥 PSMA-targeted radioligand therapy after TKI + ICI progression
🎯 Evaluating response, PFS, OS, & safety
🧠 Imaging-guided treatment w/ added cycles for responders

🎥 buff.ly/sswLUyk

#kcms #UroOnc #UroSoME

Sequencing IO and radiotherapy in nasopharyngeal carcinoma - VJOncology Jun Ma, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, comments on the potential benefits of integrating PD-1 immunotherapy (IO)...

🎥Prof. Jun Ma of Sun Yat-sen University Cancer Center, Guangzhou, China, discusses sequencing IO and radiotherapy in nasopharyngeal carcinoma:

➡️ buff.ly/K24ba3d ⬅️

#ASCO25 #ImmunOnc #hncSM

The future of CSF liquid biopsies in precision medicine for brain tumors - VJOncology Cecile Riviere-Cazaux, PhD, Mayo Clinic, Rochester, MN, highlights the emerging role cell-free DNA (cfDNA) as novel biomarkers in neuro-oncology, highlighting...

🎥Cecile Riviere-Cazaux, PhD, highlights the emerging role cfDNA as novel biomarkers in neuro-oncology, noting their ability to detect molecularly defined biomarkers and monitor treatment response:

➡️ buff.ly/xCKCsRY

#BTSM #Oncology

The future of immunotherapy in nasopharyngeal carcinoma beyond PD-1 - VJOncology Jun Ma, MD, Sun Yat-sen University Cancer Center, Guangzhou, China, discusses current immunotherapy approaches in nasopharyngeal carcinoma. There is a...

🎥Prof. Jun Ma of Sun Yat-sen University Cancer Center, Guangzhou, China, discusses current immunotherapy approaches in nasopharyngeal carcinoma:

➡️ buff.ly/egOS3ia

#ASCO25 #ImmunOnc #hncSM

Hurdles to providing equitable surgical care for ovarian cancer - VJOncology Christina Fotopoulou, MD, PhD, Imperial College London, London, UK, emphasizes the importance of accessibility as a major barrier in providing...

🎥Christina Fotopoulou, MD, PhD, of @imperialcollegeldn.bsky.social highlights accessibility as a key barrier to optimal surgical care in advanced #OvarianCancer:

Watch here➡️ buff.ly/yLzNHzG

#ESMOGynae25 #GynOnc #GyncSM #CTSM #TrialUpdate #SurgOnc

Clonal hematopoiesis monitoring as a future biomarker in mCRPC - VJOncology Aslı Doğa Munzur, BSc, Vancouver Prostate Centre, Vancouver, Canada, speaks on the potential of clonal hematopoiesis (CH) as a biomarker...

🎥Aslı Doğa Munzur, BSc, discusses clonal hematopoiesis (CH) as a potential biomarker in #mCRPC

⭐Ongoing work aims to define CH’s role in predicting blood disorder risk & guiding patient selection:

➡️https://buff.ly/Y9FKoJW

@ascocancer.bsky.social #ASCO25 #UroOnc #UroSoMe #PCSM

Post-progression CDK4/6 inhibitors in breast cancer: a failing strategy? - VJOncology Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, shares his rationale against the continuation of CDK4/6 inhibitors following disease progression...

🎥Fabrice André, MD, PhD, argues against continuing the same CDK4/6 inhibitor after progression in HR+/HER2– #BreastCancer

Watch here➡️https://buff.ly/6Uqux4A

@myesmo.bsky.social #ESMOBreast25 #BCSM

TRUST: optimal timing of surgical therapy in advanced ovarian cancer - VJOncology Christina Fotopoulou, MD, PhD, Imperial College London, London, UK, discusses the TRUST study (NCT02828618), a prospective randomized trial on the...

⭐Christina Fotopoulou, MD, PhD, reports TRUST: primary debulking surgery improved PFS in advanced ovarian cancer, though OS was similar across arms:

🎥 buff.ly/DEDNtYW

#ESMOGynae25 #GynOnc #GyncSM #CTSM #TrialUpdate #SurgOnc

ASCO 2025 highlights in breast cancer: ASCENT-04, SERENA-6, and more - VJOncology Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of key studies in...

⭐ Jason Mouabbi, MD, of @mdanderson.bsky.social, shares an overview of key studies in breast cancer presented at #ASCO25:

🎥 buff.ly/0IeuM2Z

@ascocancer.bsky.social #BCSM #BreastCancer #CTSM #TrialUpdate #ImmunoOnc

PROMISE: CE/BZA in postmenopausal, ER+ ductal carcinoma in situ - VJOncology Swati Kulkarni, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, discusses the Phase II PROMISE study (NCT02694809), which assesses...

⭐ Swati Kulkarni, MD, discusses the PROMISE study, assessing presurgical use of conjugated CE/BZA in postmenopausal women with ER-positive DCIS:

🎥 buff.ly/FJvSAAR

@ascocancer.bsky.social #ASCO25 #BreastCancer #CTSM #TrialUpadte #SurgOnc

KEYNOTE-756: pembrolizumab & neoadjuvant chemotherapy in ER+/HER2- breast cancer - VJOncology Fabrice André, MD, PhD, Gustave Roussy, Villejuif, France, discusses the Phase III KEYNOTE-756 study (NCT03725059) of pembrolizumab with neoadjuvant chemotherapy...

⭐ Fabrice André, MD, PhD, shares KEYNOTE-756 results:

➡️ Adding pembrolizumab to neoadjuvant chemo improved pCR in high-risk ER+/HER2- breast cancer. EFS data pending...

🎥 buff.ly/0R25Yjb

#ESMOBreast25 #BreastCancer #BCSM #CTSM #TrialUpdate #ImmunoOnc

Unmet needs in treating ovarian cancer in geriatric patients - VJOncology Felix Hilpert, MD, Krankenhaus Jerusalem, Hamburg, Germany, gives an overview of treatment gaps in elderly and frail patients with ovarian...

⭐ Felix Hilpert, MD, stresses that age/frailty shouldn’t preclude ovarian cancer therapy: chemo & surgery can extend survival in older pts:

🎥 buff.ly/MUxPkAI

#ESMOGynae25 #GynOnc #GyncSM

RAISN: indocyanine green-guided lymph node dissection in testicular cancer - VJOncology Yue Che, MD, University Hospital of Duesseldorf, Düsseldorf, Germany, discusses the evolving role of retroperitoneal lymph node dissection and therapy...

⭐ Yue Che, MD, shares RAISN trial: ICG-guided sentinel node biopsy is feasible & well tolerated in stage I testicular cancer, aiming to reduce chemo use:

🎥 buff.ly/kF09jHH

#EAU25 #UroOnc #UroSoMe #CTSM #TrialUpdate #TSCsm